Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Page 3 of 12
Jul 14, 2026Spero Therapeutics has committed over $1 billion to secure development rights for Innovent’s SP001, an investigational anti-CD40L antibody aimed at IgG4-related disease. With a Phase 2 study on the horizon for 2027, this deal highlights both the enduring value of innovative autoimmune therapies and the ongoing appetite for high-stakes biotech partnerships.
Jonathan Blake
Jul 14, 2026GSK’s antibody drug Jemperli showed success in a decisive Phase 2 study for patients with a rare rectal cancer subtype. This positive outcome paves the way for the company’s anticipated FDA submission and may influence future strategies for accelerated oncology drug review in the U.S.
Jonathan Blake
Jul 13, 2026While mainstream discussion centers on only two obesity-associated gene variants, hundreds of genetic factors shape individual risk. This post delves into why oversimplifying genetic causality in obesity distorts scientific understanding, clinical approaches, and public policy—and why a more nuanced view is vital for innovation.
Jonathan Blake
Jul 13, 2026The scientific community continues to make strides in understanding and treating Alzheimer’s disease. At AAIC 2026, tau protein research and blood-brain barrier breakthroughs are at the forefront, potentially reframing future therapeutic pathways. This in-depth analysis contextualizes the significance of these scientific advancements.
Daniel Cho
Jul 10, 2026A new funding push by ARPA-H funnels $160 million toward custom gene editing for rare diseases, involving seven research labs and potentially catalyzing breakthroughs across the biotech sector. While the project faced delays due to administrative transitions, this large-scale investment signals robust government backing for next-generation therapeutic technologies and could reshape the landscape for treating ultra-rare conditions.
Emily Carter
Jul 9, 2026In the wake of FDA’s policy evolution away from exclusive reliance on animal testing, startups and established companies alike are racing to refine preclinical drug testing methods. While technologies like organoids and organ-on-a-chip platforms are gaining popularity, a new push for whole-organ testing by a Connecticut-based startup may reshape industry standards for evaluating human drug response.
Daniel Cho
Jul 6, 2026Since its IPO, Veradermics has experienced exceptional gains, amassing market attention by aligning its hair loss research with the runaway success of the modern obesity drug market. CEO Reid Waldman’s acknowledgment of the consumer-driven 'weight loss craze' sheds light on shifting biotech priorities and the growing synergy between metabolic and dermatological health solutions.
Emily Carter
Jul 5, 2026The latest funding round positions Celea Therapeutics to directly challenge established IPF therapies with its next-generation candidate. This pivotal trial could have far-reaching implications for patients struggling with progressive lung disease, the biotech landscape, and future standards of care in pulmonary medicine.
Dr. Alex Morgan
Jul 5, 2026Despite economic uncertainties, the biotech industry’s stock rally continues to outperform expectations as we move through 2026. The uptrend is reshaping investor optimism, R&D priorities, and the landscape for emerging and established biotech companies.
Jonathan Blake
Jul 3, 2026For the first time, children under 12 with rare inherited blood disorders will have access to a gene therapy: Vertex’s Casgevy. The FDA’s recent approval under the agency’s National Priority Voucher program reflects both continued scientific progress and the careful approach regulators take to pediatric innovation.
Sophia Reynolds
Jul 3, 2026Roche is advancing its next-generation KRAS G12C inhibitor, divarasib, after Phase 3 data suggest it may offer greater potency and selectivity than current market options from Amgen and Bristol Myers Squibb. This announcement highlights an increasingly competitive race to address one of lung cancer’s most challenging genetic mutations and could mark a pivotal shift in standards of care for patients whose cancers are driven by KRAS G12C mutations.
Daniel Cho
Jul 3, 2026In a move poised to elevate standards in oncology, Color has introduced a new peer-to-peer component to its Expert Medical Opinion program, enabling oncologists to consult directly with top cancer specialists. This innovation could signal a transformation in how complex cancer diagnoses and treatments are validated and optimized, while amplifying the role of collaborative expertise in personalized care.
Dr. Priya NandakumarMachine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.